On Thursday, the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion for an update for Novo Nordisk A/S’ (NYSE:NVO) Ozempic (once-weekly subcutaneous ...

Zepbound (tirzepatide) and Ozempic (semaglutide) are brand-name subcutaneous injections. They’re both prescribed for weight loss and weight management, but only Zepbound has been FDA-approved for this ...

Ozempic is a drug that can help with weight loss. However, some people may experience “Ozempic rebound.” This refers to regaining weight and reversing the health benefits after they stop using the ...

Novo Nordisk NVO announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending that Ozempic’s (once-weekly ...

GLP-1 drugs are being studied in a growing number of indications, and Novo Nordisk can now claim to have the first medication in this class approved for chronic kidney disease. The FDA has expanded ...

Medicare does not cover Ozempic for prediabetes treatment, as this is considered an off-label use. However, the Medicare Diabetes Prevention Program (MDPP) is covered and can help prevent or reverse ...